CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis
Larsson, E ; Harris, H E ; Palmblad, K ; Månsson, Bengt LU
; Saxne, Tore
LU
and Klareskog, L
(2005)
In Annals of the Rheumatic Diseases
64(3).
p.494-496
- Abstract
- Objective: To investigate if administration of CNI-1493, an inhibitor of the synthesis of proinflammatory cytokines and NO, protects against development of joint destruction in collagen induced arthritis ( CIA) in rats. Methods: In a placebo controlled experiment, CNI-1493 was given once daily intraperitoneally after onset of clinical arthritis in DA rats. Disease progression was studied by clinical scoring of arthritis, serial measurement of serum levels of COMP, and histological examination of joints. Results: Clinical signs of arthritis were significantly reduced in the CNI-1493 treated group of rats in comparison with the placebo treated group. Histological examinations of paws demonstrated a significant reduction of cartilage... (More)
- Objective: To investigate if administration of CNI-1493, an inhibitor of the synthesis of proinflammatory cytokines and NO, protects against development of joint destruction in collagen induced arthritis ( CIA) in rats. Methods: In a placebo controlled experiment, CNI-1493 was given once daily intraperitoneally after onset of clinical arthritis in DA rats. Disease progression was studied by clinical scoring of arthritis, serial measurement of serum levels of COMP, and histological examination of joints. Results: Clinical signs of arthritis were significantly reduced in the CNI-1493 treated group of rats in comparison with the placebo treated group. Histological examinations of paws demonstrated a significant reduction of cartilage destruction in the CNI-1493 treated group, but marked destruction of cartilage in the placebo group. Serum levels of COMP increased in the placebo group, whereas in the CNI-1493 treated group levels were low and decreased significantly during the observation time. Conclusions: Treatment with CNI-1493 provides efficient protection against synovial inflammation and cartilage destruction when used therapeutically in CIA. The protective effect against cartilage destruction can be monitored by measuring serum COMP. These observations make CNI-1493 an attractive candidate for therapeutic studies in human arthritis, and COMP an attractive serum marker for monitoring joint protective effects. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/253939
- author
- Larsson, E
; Harris, H E
; Palmblad, K
; Månsson, Bengt
LU
; Saxne, Tore
LU
and Klareskog, L
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 64
- issue
- 3
- pages
- 494 - 496
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000226980700029
- pmid:15708902
- scopus:14144250623
- pmid:15708902
- ISSN
- 1468-2060
- DOI
- 10.1136/ard.2004.021550
- language
- English
- LU publication?
- yes
- id
- cd9105db-1519-40de-956a-b55902f8146b (old id 253939)
- date added to LUP
- 2016-04-01 17:01:29
- date last changed
- 2022-04-23 02:10:18
@article{cd9105db-1519-40de-956a-b55902f8146b,
abstract = {{Objective: To investigate if administration of CNI-1493, an inhibitor of the synthesis of proinflammatory cytokines and NO, protects against development of joint destruction in collagen induced arthritis ( CIA) in rats. Methods: In a placebo controlled experiment, CNI-1493 was given once daily intraperitoneally after onset of clinical arthritis in DA rats. Disease progression was studied by clinical scoring of arthritis, serial measurement of serum levels of COMP, and histological examination of joints. Results: Clinical signs of arthritis were significantly reduced in the CNI-1493 treated group of rats in comparison with the placebo treated group. Histological examinations of paws demonstrated a significant reduction of cartilage destruction in the CNI-1493 treated group, but marked destruction of cartilage in the placebo group. Serum levels of COMP increased in the placebo group, whereas in the CNI-1493 treated group levels were low and decreased significantly during the observation time. Conclusions: Treatment with CNI-1493 provides efficient protection against synovial inflammation and cartilage destruction when used therapeutically in CIA. The protective effect against cartilage destruction can be monitored by measuring serum COMP. These observations make CNI-1493 an attractive candidate for therapeutic studies in human arthritis, and COMP an attractive serum marker for monitoring joint protective effects.}},
author = {{Larsson, E and Harris, H E and Palmblad, K and Månsson, Bengt and Saxne, Tore and Klareskog, L}},
issn = {{1468-2060}},
language = {{eng}},
number = {{3}},
pages = {{494--496}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis}},
url = {{http://dx.doi.org/10.1136/ard.2004.021550}},
doi = {{10.1136/ard.2004.021550}},
volume = {{64}},
year = {{2005}},
}